- $12.92bn
- $13.48bn
- $4.03bn
- 99
- 58
- 65
- 87
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | 12.91 | ||
| PEG Ratio (f) | 1.23 | ||
| EPS Growth (f) | 11.73% | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 2.71 | ||
| Price to Tang. Book | 23.18 | ||
| Price to Free Cashflow | 11.69 | ||
| Price to Sales | 3.2 | ||
| EV to EBITDA | 11.15 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | 11.83% | ||
| Return on Equity | 15.2% | ||
| Operating Margin | 22.63% | ||
Financial Summary
| Year End 28th Sep | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 3,776.4 | 5,632.3 | 4,862.8 | 4,030.4 | 4,030.3 | 4,083.92 | 4,305.76 | 3.66% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | +363.03 | +68.75 | -27.61 | -50.58 | +39.88 | +16.57 | +8.41 | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Hologic, Inc. is a medical technology company primarily focused on improving women's health and well-being through early detection and treatment. The Company is a developer, manufacturer and supplier of diagnostics products, medical imaging systems, and surgical products. Its segments include Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. The Diagnostics segment offers a range of diagnostic products, which are used primarily to aid in the screening and diagnosis of human diseases. The Breast Health segment offers a broad portfolio of solutions for breast imaging, biopsy, breast surgery and pathology. The GYN Surgical segment's products include MyoSure hysteroscopic tissue removal system, NovaSure endometrial ablation system, Acessa ProVu laparoscopic radiofrequency ablation system, as well as CoolSeal vessel sealing portfolio and JustRight surgical stapler. The Skeletal Health segment's products include the Horizon DXA and the Fluoroscan Insight FD mini C-arm.
Directors
- Stephen Macmillan CHM (58)
- Karleen Oberton CFO (52)
- Sean Daugherty CEX (46)
- Kevin Thornal CEX (48)
- Jan Verstreken CEX (54)
- Elisabeth Hellmann SVP (53)
- John Griffin GCN (61)
- Sally Crawford LED (68)
- Charles Dockendorff IND (67)
- Scott Garrett IND (71)
- Ludwig Hantson IND (59)
- Namal Nawana IND (51)
- Christiana Stamoulis IND (51)
- Amy Wendell IND (61)
- Last Annual
- September 28th, 2024
- Last Interim
- December 28th, 2024
- Incorporated
- January 18th, 1990
- Public Since
- March 1st, 1990
- No. of Shareholders
- 703
- No. of Employees
- 7,063
- Sector
- Healthcare Equipment & Supplies
- Industry
- Healthcare
- Exchange
NASDAQ Global Select Market- Shares in Issue
- 224,389,612
- Address
- 250 Campus Drive, MARLBOROUGH, 1752
- Web
- https://www.hologic.com/
- Phone
- +1 5082632900
- Contact
- Michael Watts
- Auditors
- Ernst & Young LLP
Latest News for HOLX
Upcoming Events for HOLX
Q2 2025 Hologic Inc Earnings Release
Q2 2025 Hologic Inc Earnings Call
Q3 2025 Hologic Inc Earnings Release
Similar to HOLX
10X Genomics
NASDAQ Global Select Market
Accuray
NASDAQ Global Select Market
Akoya Biosciences
NASDAQ Global Select Market
Align Technology
NASDAQ Global Select Market
Alphatec Holdings
NASDAQ Global Select Market
FAQ
As of Today at 21:07 UTC, shares in Hologic are trading at $57.56. This share price information is delayed by 15 minutes.
Shares in Hologic last closed at $57.56 and the price had moved by -23.17% over the past 365 days. In terms of relative price strength the Hologic share price has underperformed the S&P500 Index by -27.76% over the past year.
The overall consensus recommendation for Hologic is Hold. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreHologic does not currently pay a dividend.
Hologic does not currently pay a dividend.
Hologic does not currently pay a dividend.
To buy shares in Hologic you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $57.56, shares in Hologic had a market capitalisation of $12.92bn.
Here are the trading details for Hologic:
- Country of listing: United States
- Exchange: NSQ
- Ticker Symbol: HOLX
Based on an overall assessment of its quality, value and momentum Hologic is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Hologic is $76.63. That is 33.13% above the last closing price of $57.56.
Analysts covering Hologic currently have a consensus Earnings Per Share (EPS) forecast of $4.26 for the next financial year.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Hologic. Over the past six months, its share price has underperformed the S&P500 Index by -21.8%.
As of the last closing price of $57.56, shares in Hologic were trading -22.16% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Hologic PE ratio based on its reported earnings over the past 12 months is 12.91. The shares last closed at $57.56.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Hologic's management team is headed by:
- Stephen Macmillan - CHM
- Karleen Oberton - CFO
- Sean Daugherty - CEX
- Kevin Thornal - CEX
- Jan Verstreken - CEX
- Elisabeth Hellmann - SVP
- John Griffin - GCN
- Sally Crawford - LED
- Charles Dockendorff - IND
- Scott Garrett - IND
- Ludwig Hantson - IND
- Namal Nawana - IND
- Christiana Stamoulis - IND
- Amy Wendell - IND